Please assess the completion status of the following clinical trial:

Trial Title: RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects =/\> 18 years and =/\< 80 years~2. Major trauma (ISS \> 15)~3. Clinical signs of ongoing bleeding or patients who are at risk for significant haemorrhage assessed and judged by the ED team in charge of patient~4. Presence of coagulopathy defined by ROTEM assays as follows,~   * Patients with concomitant decreased fibrinogen polymerisation (ROTEM® FibTEM A10 of \< 7 mm after 10 min)~  * Patients with concomitant decreased coagulation factor levels (ROTEM® ExTEM CT of \> 90 sec)~Exclusion Criteria:~1. Lethal injury~2. CPR on the scene,~3. Isolated brain injury, burn injury~4. Avalanche injury~5. Administration of FFP or coagulation factor concentrates before ED admission~6. Delayed (\> 6hours after trauma) admittance to ED~7. Known use of oral anticoagulants, or platelet aggregation inhibitors within 5 days before injury~8. Known history of severe allergic reaction to plasma products~9. Known history of congenital hemostasis disturbance, IgA or Protein C deficiency~10. Patients with a history of thromboembolic events or heparin induced thrombocytopenia (HIT) type 2 within the last year~11. Patients with a body weight \< 45kg and \> 150kg~12. Patients that are known to be pregnant~13. Jehova's Witness~14. Known participation in another clinical trial~15. Patient with known refusal of a participation in this clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Coagulation factor concentrates (Type: ACTIVE_COMPARATOR): None
- Fresh Frozen Plasma (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).